|
KMID : 0360220160570111731
|
|
Journal of the Korean Ophthalmological Society
2016 Volume.57 No. 11 p.1731 ~ p.1737
|
|
|
Short-term Effectiveness of Intravitreal Triamcinolone Injection for Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
|
|
Ahn Hyun-Min
Choi Kyoung-Sub
|
|
|
Abstract
|
|
|
Purpose: To evaluate the short-term efficacy of intravitreal triamcinolone (IVTA) injection for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO) refractory to intravitreal bevacizumab injections.
Methods: This retrospective, observational study included 23 eyes of 23 patients with macular edema secondary to BRVO. The patients with macular edema unresponsive to 2 or more consecutive monthly intravitreal bevacizumab injections were treated with IVTA. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) based on optical coherence tomography were evaluated before IVTA and 1 month and 3 months after IVTA injections.
Results: All patients were previously treated with 3.4 ± 1.2 intravitreal bevacizumab injections. The IVTA injection was performed at 4.3 ± 1.7 weeks after the last bevacizumab injection. The logarithm of the minimal angle of resolution (log MAR) BCVA was also decreased from 0.61 ± 0.45 to 0.52 ± 0.35 after 1 month and to 0.58 ± 0.37 after 3 months of IVTA, although without statistical significance (p = 0.114 and 0.412, respectively). Eight eyes (34.8%) showed more than 3 lines improvement of BCVA and 4 eyes (17.4%) showed stable BCVA increasing 2 lines or less. CFT was significantly improved from 512 ± 166 μm to 310 ± 139 μm after 1 month and to 324 ± 159 μm after 3 months of IVTA injections (p = 0.014 and 0.031, respectively).
Conclusions: IVTA was beneficial in some patients with macular edema secondary to BRVO refractory to intravitreal bevacizumab therapy. This study indicates that IVTA could be considered as a treatment option for refractory macular edema associated with BRVO.
|
|
|
KEYWORD
|
|
|
Anti-vascular endothelial growth factor, Bevacizumab, Branch retinal vein occlusion, Refractory macular edema, Triamcinolone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|